Assesses changes in HbA1c levels among non-insulin and insulin-requiring type 2 diabetes primary care patients prescribed a CGM , finding statistically significant reductions in mean HbA1c levels. Patients who visited a clinical pharmacist during their clinic visit exhibited greater reductions in HbA1c levels.

Reviews the evidence base of the benefits of CGM usage among individuals with type 2 diabetes treated with basal insulin only and/or noninsulin therapies and finds CGM use is associated with improvements in HbA1c and/or other key outcome measures.

Describes the benefits and limitations of CGM use for diabetes treatment, CGM usage in clinical settings, and the application of CGM to advanced diabetes technology.

Studies the clinical outcomes of two CGMs (Dexcom and FreeStyle Libre) in people with type 1 and type 2 diabetes and finds similar rates of acute diabetes events, hospitalizations, and HbA1c reductions between these devices.

Evaluates the benefit of CGM use and finds that seven years later, A1c was significantly lower for those who gained access to a CGM within the first year of type 1 diabetes diagnosis versus those with later CGM use or none at all.

Finds that patients with gestational diabetes using CGMs were more likely to have lower HbA1c levels at the end of pregnancy, experience less gestational weight gain, and give birth to infants with lower birth weights compared to those using blood glucose monitoring. However, the evidence is limited by the small number and size of the studies reviewed.

Finds that CGM use among pregnant individuals with diabetes is associated with lower HbA1c levels, cesarean section rates and neonatal birth weight.

Finds that CGM use over eight months among adults with insulin-treated type 2 diabetes resulted in significantly decreased HbA1C.

Analyzes recent flash CGM literature to draw conclusions on the clinical and fiscal impact of flash CGM utilization.

Finds that CGM use is associated with reductions in average blood glucose levels and other promising clinical outcomes among a small sample of mostly patients of color served by a safety-net health care facility. CGM service and follow-up care was delivered by an interdisciplinary care team, including a physician, pharmacist, and dietician.

Analyzes whether CGM efficacy depends on blood test strip usage prior to CGM initiation and found that CGM use was associated with reduced acute diabetes events regardless of baseline blood finger stick use.

Reviews literature on differences between CGM and standard care methods for glycemic control for both type 1 and type 2 diabetes and highlights the efficacy of CGM compared to other treatment methods.